Pipeline
Advancing a wholly-owned pipeline of category-defining therapeutics
Model Medicines is building a franchise of precision therapeutics for conserved biological choke points, with first-in-class, highly differentiated assets targeting multi-billion dollar markets where conventional chemistry has failed.
Drug Candidates
Model Medicines is advancing two lead assets toward the clinic, discovered using the GALILEO™ platform, each targeting a functionally essential, structurally conserved biological choke point. The two programs are differentiated by their unprecedented selectivity and broad-spectrum potential.
Third-Party Validation
Scientifically Validated by World-Class Research Institutes
Our work demonstrates how large-scale computation can uncover entirely new classes of drugs once thought unreachable.
Virology
Viral Replication: Respiratory and Liver Diseases
Developing the next generation of antivirals that have broader activity and demonstrate best-in-class antiviral characteristics
MDL-001
Lead Asset
a direct-acting pan-antiviral
Novel
Target
RdRp Thumb-1
2026
Catalyst Event
IND Submission
Oncology & Multi-Indication
Transcriptional Regulation: Oncology, I&I, Fibrosis, Neurodegenerative, CVD
Developing the next generation of BRD4 inhibitors that are potent, selective, and designed to overcome the dose-limiting hematologic toxicities.
MDL-4102
Lead Asset
a potent and selective BRD4 inhibitor
Grail
Target
BRD4
2027
Catalyst Event
IND Submission